NCT03095612View on ClinicalTrials.gov

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

November 8, 2022

Study Completion Date

March 3, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Selinexor

Selinexor once weekly oral or twice weekly oral

DRUG

Docetaxel

Docetaxel once every 3 weeks (75 mg/m2 IV)

Trial Locations (5)

15232

University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh

37232

University of Vanderbilt Medical Center-Vanderbilt-Ingram Cancer Center, Nashville

75063

University of Texas Southwestern Medical Center, Dallas

80045

University of Colorado Cancer Center, Aurora

98195

University of Washington-Seattle Cancer Care Alliance, Seattle

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER